1. Home
  2. /Report-store
  3. /Life Sciences
  4. /Diagnostics and Biotech
Report image for Point of Care Diagnostics Market Size, Share, Trends & Global Forecast 2026–2035

Point of Care Diagnostics Market Size, Share, Trends & Global Forecast 2026–2035

The Point of Care Diagnostics Market is Segmented By Product (Glucose Testing, Hb1Ac Testing, Coagulation Testing, Fertility/Pregnancy, Infectious Disease, Cardiac Markers, Thyroid Stimulating Hormone, Hematology, Primary Care Systems, Decentralized Clinical Chemistry, Feces, Lipid Testing, Cancer Marker, Blood Gas/Electrolytes, Ambulatory Chemistry, Drug of Abuse Testing, Autoimmune Diseases, Urinalysis/Nephrology), By Technology (Lateral Flow Assay, Molecular Diagnostics, Fluorescence Immunoassay, Solid Phase Assay, Other Technologies), By End-use (Clinics, Hospitals, Home, Assisted Living Healthcare Facilities, Laboratory) and Region

Report Code: LSDB1949Author Name: S DanielPublication Date: November 2026Pages: 293
Available In:
Available format: PDFAvailable format: ExcelAvailable format: Word
KAISO Research and Consulting

Point of Care Diagnostics Market Size, Share, Trends & Global Forecast 2026–2035

Publication Date: Nov 21, 2026Pages: 293
Market Size Icon
MarketSize 2025
$ 21.70Billion
Market Forecast Icon
MarketForecast 2035
$ 32.43Billion
CAGR Icon
CAGR(2026–2035)
4.10%
Largest Region Icon
LargestRegion
NorthAmerica
Fastest Growing Region Icon
FastestGrowing Region
AsiaPacific

Point of Care Diagnostics Market Overview and Definition


The Global Point of Care Diagnostics Market was valued at USD 21.70 Billion in 2025, and is projected to reach USD 32.43 Billion by 2035, growing at a CAGR of 4.10% from 2026 to 2035. The market comprises fast diagnostic devices used in hospitals, clinics, at-home healthcare services, and assisted living centers, providing decentralized diagnosis of infections, glucose testing, coagulation testing, heart tests, and new biomarkers.


Glucose tests are the leading products in the market due to the growth in the rate of diabetes and self-management. Lateral flow test is the leading technology in the market, holding a significant share of the market, whereas molecular diagnosis and fluorescence immunoassay are gaining momentum. Some of the major applications are infection tracking, chronic disease monitoring, urgent testing, and preventative tests. The leading geographic markets are North America and Europe, while Asia-Pacific has emerged as the fastest growing region.


Key Market Trends & Analysis


  1. Global Point of Care Diagnostics Market valued at USD 21.70 billion in 2025 with consistent year-on-year expansion.
  2. Market projected to reach USD 32.43 billion by 2035, growing at a compound annual growth rate of 4.10%.
  3. Glucose testing products dominate the market, representing the largest segment driven by diabetes management.
  4. Infectious disease testing accelerates due to pandemic awareness and enhanced surveillance protocols globally.
  5. Molecular diagnostics technology records fastest growth, expanding rapid infectious disease and cancer screening capabilities.
  6. Lateral flow assays maintain market dominance through established clinical adoption and cost-effectiveness.
  7. Home care settings segment captures largest share, supported by expanding patient self-testing and remote monitoring trends.
  8. North America commands approximately 37% market share, anchored by advanced healthcare infrastructure and reimbursement frameworks.
  9. United States market segment valued at approximately USD 5.50 billion in 2025, reflecting regional diagnostic sophistication.
  10. Asia-Pacific region emerges as fastest-growing geography, expanding at approximately 6.5% CAGR through forecast period.
  11. Recent strategic acquisitions and product launches strengthen competitive position of multinational diagnostics manufacturers.


The point of care diagnostics market encompasses all testing systems, reagents and consumables used to rapidly make decisions at or close to the point of care. This includes glucose monitoring systems, glucose testing systems, coagulation testing systems, fertility/pregnancy testing kits, infectious disease testing, cardiac biomarker testing, thyroid testing, haematology systems, primary care diagnostic systems, decentralised clinical chemistry systems, lipid testing systems, cancer marker detection systems, blood gas/electrolyte testing systems, ambulatory chemistry systems, drug abuse testing systems, autoimmune disease markers and urinary analysis systems.


The technologies used within this field include lateral flow immunoassay, molecular diagnostic systems, fluorescent immunoassay, solid phase and novel microfluidics. The end users include physician practices, urgent care centres, retail pharmacies, hospitals, homecare patients, assisted living centres and clinical laboratories using decentralised testing.


POCT represents a revolution in healthcare delivery providing rapid diagnosis, saving healthcare costs and improving patient care. It reduces the time taken for lab results by reducing the time from hours down to minutes, allowing immediate treatment and reducing hospitalisation. Diagnostic platforms can now be automated and miniaturised providing improved accuracy and less reliance on the skill of the operator. This removes the issue of limited skilled labour in both developed and developing healthcare systems.


Source: Kaiso Research and Consulting


POCT devices can be connected providing opportunities for remote monitoring and surveillance. This can connect to electronic health records to provide informed decisions. Increasing home diagnostics helps those suffering from chronic diseases, particularly diabetes, heart issues and infectious diseases. Regulatory approval of POCT is becoming quicker and easier. For sustainability, POCT must be efficient in the use of consumables and reduce reagent wastage.


→In March 2025, Abbott Laboratories launched FreeStyle Libre 4, its advanced continuous glucose monitor integrating real-time smartphone connectivity and automated insulin delivery system interoperability, strengthening market leadership in glucose monitoring and expanding decentralised diabetes management capabilities.


Recent Developments in the Point of Care Diagnostics Market


  1. In January 2025, The Abbott company kept on adding to its portfolio of point of care diagnostics by developing fast diagnostic tests for cardiometabolic, infectious diseases and emergency situations. The company introduced new tests for clinically important diseases, thereby making its presence strong in the decentralized health care environment.


  1. In February 2025, BD, a company that is known as Becton, Dickinson and Company, extended its BD Veritor Plus platform globally for rapid COVID-19 and influenza testings through combination, which can be done in pharmacies and ambulatory clinics at once for detection of respiratory pathogens while having capacity to respond to seasonal outbreaks.


  1. In May 2025, Roche extended the cobas liat PCR-based testing menu for the point-of-care testing market with infectious disease tests, thereby enhancing the decentralisation capabilities of molecular diagnostics and offering high-quality laboratory diagnostics at the point of care through portable instrument systems and streamlined workflows.


  1. In June 2025, The Cepheid division of Danaher Corp. obtained health product licensing from Health Canada to distribute the portable PCR test called "Xpert HIV-1 Viral Load XC" which provides results within 30 minutes and is considered to be an important milestone for instrument-free molecular diagnostics.


  1. In October 2025, Top companies in the diagnostics industry have made significant investments in the development of AI-based diagnostics and connected devices, improving algorithms for machine learning that can analyze information, enable remote monitoring, and provide clinical decision support in point-of-care systems.


Point of Care Diagnostics Market Dynamics: Drivers, Restraints, Opportunities, Challenges and Trends


Drivers: Rising chronic disease prevalence accelerates demand for continuous patient monitoring solutions.


There is increasing demand in diagnostic, self-testing and point of care technologies in disease management due to the prevalence of diseases such as diabetes, cardiovascular, respiratory and cancer. More people suffer from chronic illness and therefore demand for low cost, accessible diagnostic tests have increased. Point of care technologies such as glucose monitoring at home are becoming more popular. Diabetics are using continuous glucose monitors. An ageing population in developed countries has increased diagnostic testing. There is more of a focus on preventative healthcare and diagnosing diseases.


Restraints: High regulatory stringency and fragmented approval pathways across geographies create commercialisation barriers.


Regulatory obstacles such as strict regulations to enable trials and quality management documentation. This increases time to market and costs. Products must be submitted to each market as there are different regulations depending on the market (FDA, European CE Marking and other developing markets). This causes inefficiencies in the organisation. Reimbursement policies vary which can impact opportunities for products in the market. Diagnostics are often more innovative meaning there may not be clear clinical and economic evidence available. Disputes can occur over patents in high value added diagnostics. Specialist reagents/components can cause risk.


Opportunities: Expanding home care and remote patient monitoring markets create substantial revenue opportunities for portable diagnostics.


Point of care diagnostic solutions need to be user friendly. Chronic disease management schemes have led to increased use of glucose, coagulation and infection diagnostics at home. Connecting point of care platforms to wearable/mobile phones allows monitoring of patients. This provides opportunities for subscription models and digital therapeutics. High growth opportunities exist in emerging markets (Asia Pacific, Latin America & Africa) where there is limited laboratory infrastructure. Low cost point of care solutions will help in diagnosing both communicable and non-communicable diseases.


Challenges: Implementation barriers in resource-limited settings and healthcare system integration complexities obstruct market penetration.


There is not a standard laboratory set up to develop healthcare systems, train operators and quality assurance systems to ensure successful point of care diagnostics. Integration of diagnostics into current health records/lab systems can be difficult causing inefficiencies. Operators may not be skilled causing issues diagnosing. There is little information on cost benefit analysis on some diagnostics which can cause issues with purchasing decisions. Connected diagnostic devices pose a risk to privacy and cyber security.


Trends: Multiplex diagnostic assays and integrated testing platforms consolidate single-disease devices into comprehensive diagnostic solutions.


Multiplex diagnostics have allowed for high efficiency detection of multiple pathogens, biomarkers and diseases at the same time. This reduces costs. Microfluidics have allowed complex methods of analyte detection to be implemented within a small device. Integration of artificial intelligence has improved analysis and detection of diseases patterns. Cloud connectivity to devices has allowed for integration of a diagnostic system and disease surveillance system at a population level. Cost considerations in healthcare mean efficient use of materials is being encouraged and assays are being designed with sustainability in mind.


Where Are the Biggest Opportunities in the Point of Care Diagnostics Market?


  1. Continuous glucose monitoring integration into smartphone ecosystems and automated insulin delivery systems expands diabetes management market.
  2. Respiratory pathogen multiplex assays addressing influenza, RSV, and COVID-19 simultaneously optimise emergency department and urgent care workflows.
  3. Cancer marker point-of-care testing enables early detection protocols in primary care and screening programmes across underserved populations.
  4. Molecular diagnostics integration into pharmacy-based platforms transforms community screening for infectious diseases and sexually transmitted infections.
  5. Coagulation monitoring devices supporting anticoagulation management in home care settings reduce hospital readmission rates and improve patient outcomes.
  6. Artificial intelligence-driven diagnostic platforms automating result interpretation reduce operator dependence and standardise testing quality across healthcare settings.
  7. Connected point-of-care devices enabling remote monitoring and telehealth integration support chronic disease management programme expansion globally.
  8. Autoimmune disease point-of-care assays addressing unmet diagnostic needs in primary care settings expand screening and enable earlier therapeutic intervention.
  9. Decentralised clinical chemistry platforms replacing central laboratory testing in hospital point-of-care networks reduce turnaround times and improve emergency care efficiency.
  10. Point-of-care testing infrastructure expansion across rural and underserved regions addresses diagnostic access gaps and supports preventive health screening programmes.


Point of Care Diagnostics Market Segmentation Analysis


Report Attributes

Details

Market Size in 2025

USD 21.70 Billion

Market Size by 2035

USD 32.43 Billion

CAGR (2026-2035)

4.10%

Base Year

2025

Forecast Period

2026-2035

Historical Data

2022-2024

Report Scope & Coverage

Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, Analysis, Forecast Outlook

Key Segments

By Product:

  1. Glucose Testing
  2. Hb1Ac Testing
  3. Coagulation Testing
  4. Fertility/Pregnancy
  5. Infectious Disease
  6. HIV POC
  7. Clostridium Difficile POC
  8. HBV POC
  9. Pneumonia or Streptococcus Associated Infections
  10. Respiratory Syncytial Virus (RSV) POC
  11. HPV POC
  12. Influenza/Flu POC
  13. HCV POC
  14. MRSA POC
  15. TB and Drug-resistant TB POC
  16. HSV POC
  17. COVID-19
  18. Other Infectious Diseases
  19. Cardiac Markers
  20. Thyroid Stimulating Hormone
  21. Hematology
  22. Primary Care Systems
  23. Decentralized Clinical Chemistry
  24. Feces
  25. Lipid Testing
  26. Cancer Marker
  27. Blood Gas/Electrolytes
  28. Ambulatory Chemistry
  29. Drug of Abuse (DOA) Testing
  30. Autoimmune Diseases
  31. Urinalysis/Nephrology

By Technology: Lateral Flow Assay, Molecular Diagnostics, Fluorescence Immunoassay, Solid Phase Assay, Other Technologies

By End-use:

  1. Clinics
  2. Pharmacy & Retail Clinics
  3. Physician Office
  4. Urgent Care Clinics
  5. Non-practice Clinics
  6. Hospitals
  7. Home
  8. Assisted Living Healthcare Facilities
  9. Laboratory

Regional Analysis/Coverage

North America (U.S., Canada), Europe (UK, Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia, Africa, Rest of Latin America)

Company Profiles

F. Hoffmann-La Roche Ltd., Qiagen, Danaher Corporation, Becton Dickinson (BD), bioMérieux, Abbott, Siemens Healthcare GmbH, Werfen, Nova Biomedical, Trividia Health, Inc., QuidelOrtho Corporation, Trinity Biotech, Sekisui Diagnostics, Orasure Technologies, Inc., Spectral Medical, Inc.

Source: Kaiso Research and Consulting


Point of Care Diagnostics Market Segment Analysis


  1. By Product, Glucose Testing dominated the "Point of Care Diagnostics Market" in 2025 with approximately 18% share; Infectious Disease Testing is the fastest-growing segment with a CAGR of approximately 5.2% from 2026 to 2035.


  1. By Technology, Lateral Flow Assay dominated the "Point of Care Diagnostics Market" in 2025 with approximately 42% share; Molecular Diagnostics is the fastest-growing segment with a CAGR of approximately 6.8% from 2026 to 2035.


  1. By End-use, Home Care Settings dominated the "Point of Care Diagnostics Market" in 2025 with approximately 28% share; Hospitals is the fastest-growing segment with a CAGR of approximately 4.9% from 2026 to 2035.


Dominating Segments in the Point of Care Diagnostics Market


By Product: Glucose testing drives market dominance through established diabetes management and self-monitoring paradigms.


The glucose testing market had a 18% share of the overall market in 2025 due to its widespread use in diabetes monitoring. With the rise in diabetes, increased awareness around managing glucose and current reimbursements in place, the market continues to grow. Self-testing devices are key to ensuring those who require regular glucose monitoring can do so. The market has well-established distribution channels and is well known amongst healthcare professionals.


Continuous glucose monitoring (CGM) devices are increasing in popularity due to new smart devices being released by manufacturers. Devices like Abbott’s FreeStyle Libre have become popular as they allow the patient to monitor their glucose levels using sensors. They are able to integrate with insulin devices and smartphone apps to help patients and healthcare professionals understand their patterns and make timely changes to their treatment. This is increasing the move towards personalised treatment.


Testing for infectious diseases is expected to be one of the fastest growing markets, with a CAGR of 5.2% until 2035. Investment into monitoring infectious diseases, increased STI screening and the need for reliable diagnostics within public healthcare are driving demand. The pandemic has increased the awareness of the importance of having accessible testing and identifying new infections quickly. Tuberculosis control programmes, vaccine development and monitoring infectious diseases are continuing to drive demand for this market.


→In March 2025, Abbott advanced continuous glucose monitoring market leadership through FreeStyle Libre 4 launch, integrating real-time smartphone data transmission and automated insulin pump interoperability, enabling seamless glucose data ecosystem integration and supporting personalised diabetes management protocols.


By Technology: Lateral flow assays maintain market dominance through cost-effectiveness and established clinical validation frameworks.


The lateral flow immunoassay segment accounted for approximately 42% of the Point-of-Care Diagnostics Market in 2025. Lateral flow devices are easy to use due to their simple format and low costs. They are generally easy to operate and do not require much training. They offer results quickly without any complicated infrastructure meaning they can be used within hospitals, clinics, pharmacies and community healthcare. They also have single-use parts to help reduce handling and cross contamination. As they are scalable and have low costs to produce they are seeing high uptake.


Lateral flow assays are being used across multiple areas such as infection detection, pregnancy and general testing which has helped increase their market presence. Clinicians like to use these devices due to their portability, quick results and can help with early decision making. They are also small therefore can be used as part of decentralised testing. Manufacturers are also constantly improving these devices to increase sensitivity, specificity and ease of reading.


The molecular diagnostics segment is expected to grow the fastest with an approximate CAGR of 6.8% between now and 2035. There has been improvements in the devices to make them more portable. Reagents are becoming more efficient and the ability to use multiplexing has been improved to allow multiple targets to be detected. The use of artificial intelligence is helping simplify results. Regulatory approvals are also being granted to point-of-care molecular devices. This allows pathogens to be identified and can detect specific oncology biomarkers. This leads to quicker decisions to be made.


→In May 2025, Roche expanded cobas liat molecular diagnostics platform capabilities through new infectious disease assays, enabling point-of-care PCR testing previously requiring centralised laboratory infrastructure, advancing molecular diagnostics adoption across outpatient and community care facilities across Europe and North America.


By End-use: Home care settings capture largest market share through expanding chronic disease self-management and digital health integration.


Approximately 28% of the Point-of-Care Diagnostics Market was accounted for by the home care segment in 2025. An increase in continuous glucose monitors, smart devices and telehealth systems are allowing patients to monitor health indicators and provide this information to a healthcare practitioner. This helps to decentralise testing, decrease the number of visits to the clinic and helps manage chronic diseases.


As we see more people living longer, and a rise in the prevalence of diabetes and chronic diseases, there is an increased demand for diagnostic devices for use at home. Patients increasingly want devices to allow them to have immediate access to their health data. Over the counter devices have become available and are offering patients the chance to undertake certain diagnostic tests without any direct clinical oversight. Devices are becoming easier to use and integrating with smartphones and health tech meaning manufacturers can create devices that can easily fit in with patients’ lives.


The hospital segment is expected to be the fastest growing end user segment with an approximate CAGR of 4.9% between now and 2035. There is an increased use of point-of-care testing within emergency departments, intensive care, and other departments where quick clinical decisions need to be made. The immediate results can help clinicians understand patient status and treat them accordingly. Hospitals have also been investing in decentralised testing to help increase efficiency in the lab, increase speed of diagnosis and manage patients timely.


→In February 2025, BD announced global expansion of Veritor Plus platform for pharmacy-based COVID-19 and influenza combination testing, establishing point-of-care testing footprint across retail healthcare settings and expanding patient access to rapid respiratory pathogen diagnostics outside traditional hospital environments.


Regional Insights in the Point of Care Diagnostics Market


Regional Analysis:


Region

Major Country

Share within Region, 2025 (%)

North America

United States

68.0

Europe

Germany

24.0

Asia-Pacific

China

38.0

LAMEA

Brazil

42.0


North America: Healthcare system digitalisation and reimbursement support accelerate point-of-care diagnostics adoption.


North America was the leading region in the Point-of-Care Diagnostics Market in 2025, with the industry expected to grow at a CAGR of around 3.8% between 2025 and 2035. This is due to the high level of healthcare development within the region, therefore there is increasing demand for fast diagnostic tools. Point-of-care is being embraced more within healthcare services to increase diagnostics accessibility. Healthcare professionals are using point-of-care testing more to help reduce testing times.


The United States represents around 68% of the North American market. This is due to the availability of continuous glucose monitoring devices, the increasing usage of rapid infectious disease tests and regulatory processes to help bring these technologies to market. The increase in digital healthcare is helping increase demand for point-of-care diagnostics. Point of care can be used to integrate with electronic health records, telehealth and remote patient monitoring systems. This helps healthcare professionals reduce testing times. This can help with managing chronic conditions, increases communication between healthcare professionals and improves decentralised diagnostics.


Canada is also contributing to the growth of the point-of-care diagnostics market. The healthcare industry is focusing on increasing diagnostic efficiency. Point-of-care can help rural and remote areas. This helps healthcare professionals get quicker diagnostic results. Investment into healthcare within the community along with mobile testing devices and digital healthcare will help increase the usage of point-of-care devices.


→In January 2025, Abbott strengthened cardiometabolic point-of-care portfolio through new troponin assays enabling rapid acute coronary syndrome diagnosis in emergency departments, improving patient triage efficiency and reducing unnecessary hospitalisation across North American healthcare networks.


USA: Decentralised healthcare infrastructure and home-based monitoring programmes drive market expansion.


The United States Point-of-Care Diagnostics Market was valued at around USD 5.50 Billion in 2025. It is expected to increase to USD 7.80 Billion by 2035 (3.6% CAGR between 2026 and 2035). The United States dominates the North American market as they have large investments into healthcare, excellent diagnostics systems and increasing decentralised diagnostic testing. There is increasing demand for fast diagnostics and digital diagnostic devices. This is encouraging healthcare professionals to use these devices within hospitals, clinics, pharmacies and at-home.


There is increasing demand for diagnostics due to diabetes. Continuous glucose monitoring is becoming popular. Patients are engaging in self-management programs, insurance covers the correct glucose monitoring devices and it integrates well with digital healthcare. Patients and healthcare professionals can get more information regarding their glucose levels and make informed decisions. Rapid Infectious Disease Testing and Troponin testing for suspected acute coronary syndromes are also helping increase point-of-care usage within emergency departments.


More telehealth and remote patient monitoring programs are increasing opportunities for digital diagnostics. Digital healthcare can integrate with these point-of-care devices to help clinicians monitor patients remotely. This can help clinicians notice any changes which may need medical attention, therefore reducing unnecessary trips to the hospital. Pharmacies are also increasing diagnostic testing. Some pharmacies offer testing for respiratory pathogens and some STIs, depending on regulations. This is increasing the usage within the community.


→In February 2025, Roche received FDA 510(k) clearance for cobas Liat Bordetella assay, enabling rapid whooping cough diagnosis at point-of-care and supporting pertussis surveillance and outbreak response protocols across US emergency departments and urgent care clinics.


Europe: Regulatory harmonisation and health equity programmes expand point-of-care testing accessibility.


The Europe Point-of-Care Diagnostics Market is expected to grow at a CAGR of around 4.2% up to 2035. Germany is leading the market with around 24% of the market share. They have a highly developed diagnostics industry with strong reimbursement and healthcare systems. They have strong medical technology and diagnostic capabilities.


The United Kingdom will see the highest growth rate within the region at around 5.1% thanks to National Health Service initiatives to improve point-of-care testing and better healthcare access in rural areas. France and Italy are also contributing significantly to the market. They have strong molecular diagnostic capabilities, infectious disease testing and investment into modern diagnostic systems. More demand for fast diagnostics is driving healthcare providers to use portable diagnostic systems.


The Europe region has good regulation systems in place. This allows products to be approved with CE marking under European medical device regulations. However, manufacturers will need to adhere to the correct regulations. The pressure on healthcare budgets is driving healthcare providers to consider decentralised diagnostics. Point-of-care diagnostics can reduce reliance on centralised labs for certain tests, speeding up the process.


→In May 2025, Roche announced cobas liat platform expansion with new influenza and RSV combination assay, enabling simultaneous respiratory pathogen detection across European urgent care and hospital emergency departments during seasonal disease outbreaks.


Asia-Pacific: Expanding healthcare infrastructure and infectious disease surveillance priorities drive rapid market growth.


The Asia-Pacific region is predicted to be the fastest growing region within the global point-of-care diagnostics market at a CAGR of approximately 6.5%. This is due to increased healthcare spending, diagnostic infrastructure and increased demand for accessible diagnostic testing. China has around 38% of the market share due to increased healthcare spending, a focus on infectious disease testing and government initiatives to improve diagnostics. There has been increased adoption of fast diagnostics in hospitals, community clinics and public health sectors.


India is also a significant contributor to the market growth. This is due to high volumes of infectious disease testing, tuberculosis prevention and point-of-care testing in rural areas. The government is investing in primary healthcare to improve access to diagnostics. Japan is leading the way with point-of-care diagnostics with widespread adoption of continuous glucose monitoring systems, healthcare needs with an aging population and automated diagnostic systems. Different healthcare needs are driving demand for diagnostics.


Many countries in Southeast Asia are also contributing to the market growth. Investment into healthcare infrastructure, community healthcare and decentralised diagnostic testing have increased. Portable diagnostic devices can be used to overcome geographical issues and to reduce reliance on centralised labs. Emerging markets have a high need for low cost, fast diagnostic devices. Therefore, manufacturers are producing cost-effective solutions with easy to use diagnostic devices to fit different healthcare systems.


→In June 2025, Abbott expanded glucose monitoring market share across Asia-Pacific through FreeStyle Libre 4 launch, enabling smartphone-integrated continuous monitoring and supporting diabetes management in urban and rural healthcare settings across China, India, and Southeast Asian markets.


Japan: Ageing population demographics and healthcare efficiency priorities drive point-of-care diagnostics adoption.


The market in Japan is a well-established segment which is predicted to grow at a CAGR of 3.2% up to 2035. This can be attributed to the advanced healthcare system, well-developed insurance reimbursement system and widespread uptake of technology related to diabetes management. There is significant use of continuous glucose monitors and rapid point-of-care diagnostics within both hospitals and outpatients. This is due to the need to improve diagnosis speed and to ensure Japan's ageing population can utilise healthcare.


There is increasing focus on infectious disease detection and preparedness leading to increased implementation of molecular point-of-care technologies. Molecular point-of-care tests can help increase the detection speed of certain pathogens. With increased spending in healthcare there is growing interest in using point-of-care diagnostics to reduce reliance on central testing facilities. Point-of-care testing can help reduce test complexity.


Integration with digital healthcare technologies is allowing new opportunities within diagnostics. Connected devices, electronic health records and telehealth devices allow improved sharing of diagnostic information between patients and healthcare workers. Companies such as Sysmex Corporation and Sekisui Diagnostics provide diagnostics within Japan. New products will continue to be developed, with automation and integration with digital healthcare technologies to shape the future of the point-of-care diagnostic market in Japan.


→In July 2025, Sysmex Corporation launched automated point-of-care haematology analysis platform, enabling rapid complete blood count testing in hospital point-of-care laboratories and supporting emergency department diagnostic efficiency across Japanese healthcare networks.


LAMEA: Infectious disease surveillance and healthcare access expansion drive diagnostic testing demand growth.


The Latin America, Middle East and Africa (LAMEA) Point-of-Care Diagnostics Market is expected to grow at a CAGR of 4.6% up to 2035 due to healthcare infrastrucure development, increased access to diagnostics and increased investment into decentralised diagnostics. Brazil accounts for ~42% of the Latin America market due to the need for infectious disease diagnostics, healthcare modernisation and increased diagnostic capabilities within the region. Investment into community healthcare services and rapid diagnostics is driving growth of the market.


The Middle East is helping to drive growth in the regional market through healthcare digitalisation, investment in diagnostic infrastructure and improvements in healthcare efficiency. Governments and healthcare providers are looking to invest in high-tech diagnostics to improve patient management. Africa has a strong relationship with the need for diagnostics due to communicable diseases and limited centralised labs. Investment in community healthcare services is helping to drive investment into decentralised diagnostics.


Demand in the LAMEA region is largely driven by the need for cost effective diagnostics that are easy to use, easy to transport and provide fast results. This makes them ideal for low resource healthcare facilities and remote communities. TB and Malaria screening programs, along with infectious disease surveillance, are providing opportunities for rapid diagnostics. Continued investment in healthcare infrastructure, diagnostic staff and community healthcare will help to increase adoption in developing regions.


→In September 2025, Abbott announced infectious disease point-of-care platform expansion across Brazilian public health system, deploying rapid diagnostic solutions for tuberculosis, malaria, and dengue screening supporting national disease surveillance and control programme priorities.


How Can Stakeholders Benefit from the Point of Care Diagnostics Market Report?


  1. The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
  2. The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
  3. Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
  4. A detailed examination of market segmentation helps identify existing and emerging opportunities.
  5. Key countries within each region are analysed based on their revenue contributions to the overall market.
  6. The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
  7. The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.



Chapter 1 MARKET SNAPSHOT


1.1 Market Definition & Report Overview

1.2 Scope of the Study

1.3 Research Methodology

1.3.1 Research Objective

1.3.2 Supply Side Analysis

1.3.3 Demand Side Analysis

1.3.4 Forecasting Models


Chapter 2 EXECUTIVE SUMMARY


2.1 CEO/CXO Standpoint

2.2 Key Findings


Chapter 3 INDUSTRY LANDSCAPE


3.1 Trade Analysis

3.1.1 Tariff Regulations and Landscape

3.1.2 Export - Import Analysis

3.1.3 Impact of US Tariff

3.2 Key Takeaways

3.2.1 Top Investment Pockets

3.2.2 Top Winning Strategies

3.2.3 Market Indicators Analysis

3.3 Patent Analysis

3.4 Market Dynamics

3.4.1 Drivers

3.4.2 Restraint

3.4.3 Opportunity

3.4.4 Challenges

3.5 Porter’s 5 Force Model

3.5.1 Bargaining power of buyer

3.5.2 Threat of Substitutes

3.5.3 Bargaining power of supplier

3.5.4 Threat of new entrants

3.5.5 Industry rivalry (Barriers of Market Entry)

3.6 Value Chain Analysis

3.7 PESTEL Analysis

3.8 Technology Analysis

3.8.1 Key Technology Trends

3.8.2 Adjacent Technology

3.8.3 Complementary Technologies

3.9 Pricing Analysis and Trends

3.10 Market Share Analysis (2025)


Chapter 4. Global Point of Care Diagnostics Market Size & Forecasts by Product 2026-2035


4.1. Market Overview

4.2. Glucose Testing

4.2.1. Current Market Trends, and Opportunities

4.2.2. Market Size Analysis by Region, 2026-2035

4.2.3. Market Share Analysis by Top Countries, 2026-2035

4.3. Hb1Ac Testing

4.4. Coagulation Testing

4.5. Fertility/Pregnancy

4.6. Infectious Disease

4.6.1. Hb1Ac Testing

4.6.2. Coagulation Testing

4.6.3. Fertility/Pregnancy

4.6.4. Infectious Disease

4.7. Hb1Ac Testing

4.8. Coagulation Testing

4.9. Fertility/Pregnancy

4.10. Infectious Disease


Chapter 5. Global Point of Care Diagnostics Market Size & Forecasts by Technology 2026-2035


5.1. Market Overview

5.2. Lateral Flow Assay

5.2.1. Current Market Trends, and Opportunities

5.2.2. Market Size Analysis by Region, 2026-2035

5.2.3. Market Share Analysis by Top Countries, 2026-2035

5.3. Molecular Diagnostics

5.4. Fluorescence Immunoassay

5.5. Solid Phase Assay

5.6. Other Technologies


Chapter 6. Global Point of Care Diagnostics Market Size & Forecasts by End-use 2026-2035


6.1. Market Overview

6.2. Clinics

6.2.1. Pharmacy & Retail Clinics

6.2.2. Physician Office

6.2.3. Urgent Care Clinics

6.2.4. Non-practice Clinics

6.2.4.1. Current Market Trends, and Opportunities

6.2.4.2. Market Size Analysis by Region, 2026-2035

6.2.4.3. Market Share Analysis by Top Countries, 2026-2035

6.3. Pharmacy & Retail Clinics

6.4. Physician Office

6.5. Urgent Care Clinics

6.6. Non-practice Clinics


Chapter 7. Global Point of Care Diagnostics Market Size & Forecasts by Region 2026-2035


7.1. Regional Overview 2026-2035

7.2. Top Leading and Emerging Nations

7.3. North America Point of Care Diagnostics Market

7.3.1. U.S. Point of Care Diagnostics Market

7.3.1.1. Product breakdown size & forecasts, 2026-2035

7.3.1.2. Technology breakdown size & forecasts, 2026-2035

7.3.1.3. End-use breakdown size & forecasts, 2026-2035

7.3.2. Canada

7.3.3. Mexico

7.4. Europe Point of Care Diagnostics Market

7.4.1. UK Point of Care Diagnostics Market

7.4.1.1. Product breakdown size & forecasts, 2026-2035

7.4.1.2. Technology breakdown size & forecasts, 2026-2035

7.4.1.3. End-use breakdown size & forecasts, 2026-2035

7.4.2. Germany

7.4.3. France

7.4.4. Spain

7.4.5. Italy

7.4.6. Rest of Europe

7.5. Asia Pacific Point of Care Diagnostics Market

7.5.1. China Point of Care Diagnostics Market

7.5.1.1. Product breakdown size & forecasts, 2026-2035

7.5.1.2. Technology breakdown size & forecasts, 2026-2035

7.5.1.3. End-use breakdown size & forecasts, 2026-2035

7.5.2. India

7.5.3. Japan

7.5.4. Australia

7.5.5. South Korea

7.5.6. Rest of APAC

7.6. LAMEA Point of Care Diagnostics Market

7.6.1. Brazil Point of Care Diagnostics Market

7.6.1.1. Product breakdown size & forecasts, 2026-2035

7.6.1.2. Technology breakdown size & forecasts, 2026-2035

7.6.1.3. End-use breakdown size & forecasts, 2026-2035

7.6.2. Argentina

7.6.3. UAE

7.6.4. Saudi Arabia (KSA)

7.6.5. Africa

7.6.6. Rest of LAMEA


Chapter 8. Company Profiles


8.1. Top Market Strategies

8.2. Company Profiles

8.2.1. F. Hoffmann-La Roche Ltd

8.2.1.1. Company Overview

8.2.1.2. Key Executives

8.2.1.3. Company Snapshot

8.2.1.4. Financial Performance

8.2.1.5. Product/Services Portfolio

8.2.1.6. Recent Development

8.2.1.7. Market Strategies

8.2.1.8. SWOT Analysis

8.2.2. Qiagen

8.2.2.1. Company Overview

8.2.2.2. Key Executives

8.2.2.3. Company Snapshot

8.2.2.4. Financial Performance

8.2.2.5. Product/Services Portfolio

8.2.2.6. Recent Development

8.2.2.7. Market Strategies

8.2.2.8. SWOT Analysis

8.2.3. Danaher Corporation

8.2.3.1. Company Overview

8.2.3.2. Key Executives

8.2.3.3. Company Snapshot

8.2.3.4. Financial Performance

8.2.3.5. Product/Services Portfolio

8.2.3.6. Recent Development

8.2.3.7. Market Strategies

8.2.3.8. SWOT Analysis

8.2.4. Becton Dickinson (BD)

8.2.4.1. Company Overview

8.2.4.2. Key Executives

8.2.4.3. Company Snapshot

8.2.4.4. Financial Performance

8.2.4.5. Product/Services Portfolio

8.2.4.6. Recent Development

8.2.4.7. Market Strategies

8.2.4.8. SWOT Analysis

8.2.5. bioM-rieux

8.2.5.1. Company Overview

8.2.5.2. Key Executives

8.2.5.3. Company Snapshot

8.2.5.4. Financial Performance

8.2.5.5. Product/Services Portfolio

8.2.5.6. Recent Development

8.2.5.7. Market Strategies

8.2.5.8. SWOT Analysis

8.2.6. Abbott

8.2.6.1. Company Overview

8.2.6.2. Key Executives

8.2.6.3. Company Snapshot

8.2.6.4. Financial Performance

8.2.6.5. Product/Services Portfolio

8.2.6.6. Recent Development

8.2.6.7. Market Strategies

8.2.6.8. SWOT Analysis

8.2.7. Siemens Healthcare GmbH

8.2.7.1. Company Overview

8.2.7.2. Key Executives

8.2.7.3. Company Snapshot

8.2.7.4. Financial Performance

8.2.7.5. Product/Services Portfolio

8.2.7.6. Recent Development

8.2.7.7. Market Strategies

8.2.7.8. SWOT Analysis

8.2.8. Werfen

8.2.8.1. Company Overview

8.2.8.2. Key Executives

8.2.8.3. Company Snapshot

8.2.8.4. Financial Performance

8.2.8.5. Product/Services Portfolio

8.2.8.6. Recent Development

8.2.8.7. Market Strategies

8.2.8.8. SWOT Analysis

8.2.9. Nova Biomedical

8.2.9.1. Company Overview

8.2.9.2. Key Executives

8.2.9.3. Company Snapshot

8.2.9.4. Financial Performance

8.2.9.5. Product/Services Portfolio

8.2.9.6. Recent Development

8.2.9.7. Market Strategies

8.2.9.8. SWOT Analysis

8.2.10. Trividia Health, Inc.

8.2.10.1. Company Overview

8.2.10.2. Key Executives

8.2.10.3. Company Snapshot

8.2.10.4. Financial Performance

8.2.10.5. Product/Services Portfolio

8.2.10.6. Recent Development

8.2.10.7. Market Strategies

8.2.10.8. SWOT Analysis

8.2.11. QuidelOrtho Corporation

8.2.11.1. Company Overview

8.2.11.2. Key Executives

8.2.11.3. Company Snapshot

8.2.11.4. Financial Performance

8.2.11.5. Product/Services Portfolio

8.2.11.6. Recent Development

8.2.11.7. Market Strategies

8.2.11.8. SWOT Analysis

8.2.12. Trinity Biotech

8.2.12.1. Company Overview

8.2.12.2. Key Executives

8.2.12.3. Company Snapshot

8.2.12.4. Financial Performance

8.2.12.5. Product/Services Portfolio

8.2.12.6. Recent Development

8.2.12.7. Market Strategies

8.2.12.8. SWOT Analysis

8.2.13. Sekisui Diagnostics

8.2.13.1. Company Overview

8.2.13.2. Key Executives

8.2.13.3. Company Snapshot

8.2.13.4. Financial Performance

8.2.13.5. Product/Services Portfolio

8.2.13.6. Recent Development

8.2.13.7. Market Strategies

8.2.13.8. SWOT Analysis

8.2.14. Orasure Technologies, Inc.

8.2.14.1. Company Overview

8.2.14.2. Key Executives

8.2.14.3. Company Snapshot

8.2.14.4. Financial Performance

8.2.14.5. Product/Services Portfolio

8.2.14.6. Recent Development

8.2.14.7. Market Strategies

8.2.14.8. SWOT Analysis

8.2.15. Spectral Medical, Inc.

8.2.15.1. Company Overview

8.2.15.2. Key Executives

8.2.15.3. Company Snapshot

8.2.15.4. Financial Performance

8.2.15.5. Product/Services Portfolio

8.2.15.6. Recent Development

8.2.15.7. Market Strategies

8.2.15.8. SWOT Analysis


Research Methodology


Kaiso Research and Consulting follows an independent approach in making estimations to provide unbiased business intelligence. Our studies are not limited to secondary research alone but are built on a balanced blend of primary research, surveys, and secondary sources. This methodology enables us to develop a comprehensive 360-degree understanding of the industry and market landscape.


Supply and Demand Dynamics:


A. Supply Side Analysis:


We begin by assessing how suppliers contribute to overall market revenue growth. Our research then delves into their product portfolios, geographical reach, core focus areas, and key strategic initiatives. As most of our reports are based on a top-down approach, we begin by conducting interviews across the value chain. In the first round, we engage with manufacturers and companies, speaking with professionals from supply chain management, production, and sales. These discussions allow us to gather detailed insights into revenue generation, measured in millions or billions, segmented by type, platform, end-user, region, and other key parameters. This helps identify how companies are driving their products into mainstream markets and influencing the overall industry structure.


As the final step, we conduct a Pareto analysis to evaluate market fragmentation and identify the key players influencing industry structure. On the supply side, we evaluate how industry players contribute to overall market growth and revenue generation.


This includes an in-depth review of:


  1. Product Offerings – range, categories, and applications covered.
  2. Geographical Presence – regions of operation and market penetration.
  3. Strategic Initiatives – new product development, product launches, distribution channel strategies, and key application areas.


B. Demand Side Analysis:


Once supply dynamics are assessed, we then examine demand-side factors shaping the market. This involves mapping demand across applications, geographies, and end-user groups. On the demand side, we conduct interviews with a network of distributors from the organised market to gain a deeper understanding of demand dynamics. This analysis covers revenue generation segmented by type, platform, end-user, and region.


Each subsegment is interconnected to understand patterns in:


  1. Revenue contribution
  2. Growth rate
  3. Adoption levels


By aggregating demand from all subsegments, we estimate the magnitude of market-driving forces. Comparing supply and demand enables us to forecast how these dynamics influence future market behaviour.


Forecast Model (Proprietary Kaiso Engine):


Building on quantitative rigor, Kaiso integrates a Forecast Model that blends statistical precision with strategic scenario planning. Unlike generic projections, this model adapts dynamically to evolving market signals.


Our proprietary forecast engine incorporates the following layers:


  1. Baseline Projection: Derived using historical patterns, econometric baselines, and validated macroeconomic inputs.


  1. Scenario Forecasting: Optimistic, conservative, and base-case outlooks built with dynamic weighting of influencing variables (e.g., policy shifts, raw material volatility, supply chain disruptions).


  1. AI-Augmented Predictive Analytics: Machine learning algorithms detect emerging weak signals, nonlinear patterns, and correlation anomalies that standard models may overlook.


  1. Sector-Specific Modules: Tailored sub-models for fast-evolving industries (e.g., clean energy adoption curves, healthcare regulatory cycles, AI penetration trends).


  1. Resilience Testing: Shock modeling to evaluate market response under “black swan” or disruption scenarios such as pandemics, trade wars, or technology breakthroughs.


Deliverable outcomes of our Forecast Model:


  1. Granular projections by region, segment, and application (up to 2035)


  1. Sensitivity-rank matrices highlighting critical drivers and risks


  1. Dynamic update capability, ensuring forecasts remain current with real-time data

This ensures that our clients don’t just see where the market is heading, but also how robust that trajectory is under different conditions.


Approach & Methodology


At Kaiso Research and Consulting, we adopt an independent, data-driven approach to ensure objective and unbiased insights. Our methodology blends primary research, secondary research, and survey-based validation, giving us a 360° market perspective.


Research Phase


Description


Key Activities


Secondary Research

Gathering qualitative insights from a variety of credible sources.

Analysis of blogs, articles, presentations, interviews, annual reports, and premium databases such as Hoovers, Factiva, Bloomberg.

Primary Research Phase 1: CXO Perspective

Interviews with top-level executives to collect strategic insights on trends and market drivers.

Discussions with CEOs, CXOs, industry leaders; interpretation of executive viewpoints.

Primary Research Phase 2: Quantitative Data Generation

Data collection from key stakeholders along the value chain, segmented by supply and demand.

Step 1: Interviews with manufacturers and supply chain personnel to gauge revenue metrics.

Step 2: Interviews with distributors to assess demand-side revenues.

Primary Research Phase 3: Validation

Ground-level survey research for real-world data validation across the value chain.

Collaboration with local survey companies; engagement with manufacturers, wholesalers, retailers, and end-users.


On average, for each market:


  1. 45 primary interviews are conducted covering the entire value chain.
  2. Interviews last approximately 28 minutes each, including a mix of face-to-face and online formats.


This rigorous methodology guarantees realistic, credible, and unbiased market analysis.


Key Player Positioning


We assess key companies on two major dimensions:


Market Positioning: measured through revenue, growth rate, geographical reach, customer base, strategies implemented, and focus areas.


Competitive Strength: evaluated through product portfolio, R&D investment, innovation, new product introductions, and overall competitiveness.


Conclusion


Our comprehensive methodology enables us to deliver high-quality, objective, and actionable market intelligence. By balancing both supply and demand perspectives, Kaiso Research and Consulting has established itself as a trusted and recognised brand in the research and consulting landscape.


REPORT DETAILS

Data Point:500+

Companies Covered:15+

Tables:120+

Charts / Figures:80+

Market Indicators:220+ Analysed

Available Format:PDF and Excel Data Pack

Need a Custom Report?

Tailor this report to your exact business needs with our customization service.

WHY CHOOSE KAISO RESEARCH?

  • Trusted by 5000+ clients worldwide
  • In-depth primary & secondary research
  • Data backed by verified sources
  • Actionable insights for strategic decisions
  • Dedicated support from research experts

REPORT BENEFITS

  • Comprehensive market understanding
  • Identify growth opportunities
  • Make data-driven decisions
  • Benchmark against competitor
  • Strategic planning support
Kaiso Logo
Location IconOffice 205 N Michigan Ave, Chicago, Illinois 60601, USA
YouTubeInstagramLinkedIn

We Accept

Payment MethodPayment MethodPayment MethodPayment MethodPayment MethodPayment Method

About

  • About us
  • What We Believe
  • Our Mission
  • Blogs & News

Company

  • Privacy Policy
  • Terms & Conditions
  • GDPR Policy
  • Disclaimer
  • Return & Refund Policy
  • Delivery Formats
  • Cookie Policy

Contact Us

  • Request for Consultation
  • Contact Us
  • Career
  • How to Order
  • Become a Reseller
  • FAQs

Contact Detail

Phone icon+1 872 219 0417
Phone icon+91 91835 80078
Email icon[email protected]

Keep in touch

Sign up for emails

Services

    Syndicate Reports
    Custom Report Solutions
    Full Time Engagement Models (FTE)
    Strategic Growth Solutions
    Consulting Services

Industries

    Popular Reports

      Healthcare IT
      Consumer Electronics
      Renewable and Specialty Chemicals
      Engineering, Equipment and Machinery
      Nutraceuticals and Wellness Foods
      Green, Alternative, and Renewable Energy

      Semiconductors
      Electric and Hybrid Vehicles
      Enterprise and Consumer IT Solutions
      Commercial Aviation
      Financial Services

    © 2025 Kaiso Research and Consulting. All Rights Reserved.

    ISO 9001 : 2015

    Privacy PolicyTerms & ConditionsHow to OrderSiteMap
    +1 872 219 0417+91 91835 80078
    [email protected]
    KAISO Logo
    Services
    Dropdown
    Report Store
    Dropdown
    Consulting Services
    Dropdown
    Blogs & NewsAbout Us
    Dropdown
    Search
    Logo
    Search
    Services►
    Report Store►
    Consulting Services►
    Blogs & News
    About Us►